PCI Biotech: Update on the preclinical research collaboration agreement with AstraZeneca
Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research collaboration with AstraZeneca.
The collaboration was initiated in September 2015 to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the delivery of AstraZeneca's nucleic acid therapeutic compounds. The evaluation of the potential for a further collaboration now runs to the end of 2020.
Per Walday, CEO
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS14.8.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Kommuninvest Bonds, 2020-08-18 Maturity dateLoanISIN codeCouponVolume, SEK million2022-06-012206SE00092694180.25 %500 +/- 2502023-11-132311SE00109482401.00 %500+/- 2502025-05-12 2505 SE0011414010 1.00 % 500+/- 250 2026-11-12 2611 SE0012569572 1.00 % 500+/- 250 Maximum volume 2 000 million in total Settlement date 2020-08-20 Bids have to be entered by 11.00 on AUG 18, 2020 Highest permitted bid volume: 500 SEK million in issue 2206, 2311, 2505, and 2611. Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 11.15 (CEST) ON AUG 18, 2020 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
CONDITIONS FOR RIKSBANK BID PROCEDURES SEK GOVERNMENT BONDS14.8.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2020-08-21 Maturity dateLoanISIN codeCouponVolume, SEK million2028-05-121060SE00094963670.75 %1000 +/- 2502031-05-121062 SE00139353190.125 1000 +/- 250 Settlement date 2020-08-25 Bids have to be entered by 10.00 on AUG 21, 2020 Highest permitted bid volume: 1000 SEK million in issue SGB 1060 and 1000 SEK million in issue SGB 1062 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON AUG 21, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
SEK CREDIT OPERATION ANNOUNCEMENT14.8.2020 16:20:00 CEST | Press release
SEK CREDIT OPERATION ANNOUNCEMENT 2020-08-18 Transaction type:SEK CreditTender date:2020-08-18Time for submission of bids:11.00-11.30 (CEST)Payment date:2020-08-18 (at 3 pm)Maturity date:2020-11-16Duration:13 weeks. For credit in consequence of the auction on 18 August 2020, the maturity is however 12 weeks and 6 daysOffered volume:UnlimitedLowest accepted bid volumeSEK 50 millionMaximum number of bids from each participant: 1RateRepo rate Transaction type:SEK CreditTender date:2020-08-18Time for submission of bids:11.00-11.30 (CEST)Payment date:2020-08-18 (at 3 pm)Maturity date:2021-02-15Duration:26 weeks. For credit in consequence of the auction on 18 August 2020, the maturity is however 25 weeks and 6 days. Offered volume:UnlimitedLowest accepted bid volumeSEK 50 millionMaximum number of bids from each participant: 1RateRepo rate All monetary counterparties are invited to submit volume bids to the Riksbank, tel + 46 8 6966970 by 11.30 am on August 18, 2020. Confirmation of bids to e
CONDITIONS FOR RIKSBANK BID PROCEDURES SEK COVERED BONDS14.8.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Covered Bonds, 2020-08-20 Maturity dateLoanISIN codeCouponVolume, SEK million2025-09-175535 SE00133584131.00 %1,000 +/- 5002024-12-18579 SE00121936211.00 %1,000 +/- 500 2024-12-031589SE00116433861.50 %1,000 +/- 5002025-06-18195SE00135460661.00 %1,000 +/- 5002024-12-182412SE00126218521.00 %400 +/- 2502025-09-17518SE00113092441.25 %400 +/- 2502025-06-11146SE00133815711.00 %400 +/- 250 Settlement date 2020-08-24 Bids have to be entered by 10.00 on AUG 20 2020 Highest permitted bid volume: 1,000 SEK million in issue 5535 1,000 SEK million in issue 579 1,000 SEK million in issue 1589 1,000 SEK million in issue 195 400 SEK million in issue 2412 400 SEK million in issue 518 400 SEK million in issue 146 Maximum volume 5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON AUG 20, 2020. For more information, please conta
NEXSTIM ABP:S HALVÅRSRAPPORT 1/1–30/6 2020 (OREVIDERAD)14.8.2020 14:00:00 CEST | Pressemelding
Företagsmeddelande, Insiderinformation, Helsingfors 14 augusti 2020 kl. 15.00 (EEST) NEXSTIM ABP:S HALVÅRSRAPPORT 1/1–30/6 2020 (OREVIDERAD) Viktiga händelser januari–juni 2020 Vi fokuserade på att minimera effekterna av covid-19-pandemin och utforma en ny strategi. Med tanke på den svåra affärsmiljön gjorde vi goda framsteg genom att sälja fyra nya NBS-system, tre i USA och ett i EU och installera fem nya NBT®-system på kliniker i USA och Europa för behandling av egentlig depression. Halvåret 1/1–30/6 2020 var det bästa någonsin för bolaget, med avseende på omsättningen, rörelseresultatet och räkenskapsperiodens resultat. Bolagets totala omsättning under första halvåret var 1,6 miljoner euro (H1 2019: 1,2 mn euro), rörelseresultatet var -1,8 miljoner euro (H1 2019: -3,4 mn euro) och räkenskapsperiodens resultat var -1,2 miljoner euro (H1 2019: -3,7 mn euro). Under första halvåret ökade omsättningen för NBS (med 47 %) till 0,9 miljoner euro (H1 2019: 0,2 mn euro) och för NBT (med 18 %)
NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2020 (UNAUDITED)14.8.2020 14:00:00 CEST | Press release
Company announcement, Inside Information, Helsinki, 14 August 2020 at 15:00 (EEST) NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2020 (UNAUDITED Highlights, January – June 2020 Focused on minimizing the effect of COVID-19 pandemic as well as updating company strategy. Considering the difficult business environment, good progress with four new NBS systems sold, three in the US one in the EU and a total of five new NBT® systems installed to clinics in the US and Europe, across multiple sites, for the treatment of Major Depressive Disorder (MDD) January 1 – June 30, 2020 was historically the Company’s best first half to date when measured by net sales, operating result and result for the period. The total net sales in the first half was EUR 1.6 million (2019 H1: EUR 1.2 million), operating result EUR -1.8 million (2019 H1: -3.4 million) and result for the period EUR -1.2 million (2019 H1: EUR -3.7 million) NBS net sales grew by 47% in H1 to EUR 0.9 million (2019 H1: EUR 0.6 million)